Clinical Trials

More documents

Recommendations

Info

■■❚❙❘Chapter 10Crossover <strong>Trials</strong>Duolao Wang, Ulrike Lorch, and Ameet BakhaiCrossover trials are designed so that each recruited patientreceives both active and control treatments in either orderfor a specified duration, with a ‘washout’ period betweentreatments when no treatment is administered. In such trials,patients act as their own controls, therefore fewer patientsare required to evaluate the effects of different therapiesthan in a trial with a parallel design. There are also limitationsto the crossover design, however, and here, in this chapter, wediscuss the advantages and disadvantages of crossover trials.91
Page 8:
❘❙❚■ ContributorsStephen L
Page 11 and 12:
Clinical Trials: A Practical Guide
Page 13 and 14:
Page 15:
Page 19 and 20:
■■❚❙❘Chapter 1RandomizedC
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
❘❙❚■ Chapter 2 | Uncontroll
Page 36 and 37:
Page 38 and 39:
Page 41 and 42:
■■❚❙❘Chapter 3Protocol De
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
■■❚❙❘Chapter 4EndpointsAm
Page 57 and 58: Clinical Trials: A Practical Guide
Page 65 and 66: ■■❚❙❘Chapter 5Patient Sel
Page 73 and 74: ■■❚❙❘Chapter 6Source and
Page 83 and 84: ■■❚❙❘Chapter 7Randomizati
Page 91: Clinical Trials: A Practical Guide
Page 94 and 95: ❘❙❚■ Chapter 8 | BlindingBl
Page 96 and 97: ❘❙❚■ Chapter 8 | BlindingTh
Page 98 and 99: ❘❙❚■ Chapter 8 | BlindingAs
Page 100 and 101: ❘❙❚■ Chapter 9 | Sample Siz
Page 107: ■■❚❙❘Part IIAlternativeTr
Page 119 and 120: ■■❚❙❘Chapter 11Factorial
Page 131 and 132: ■■❚❙❘Chapter 12Equivalenc
Page 137 and 138: ■■❚❙❘Chapter 13Bioequival
Page 149 and 150: ■■❚❙❘Chapter 14Noninferio
Page 159 and 160:
■■❚❙❘Chapter 15Cluster Ra
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
■■❚❙❘Chapter 16Multicente
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181:
Page 184 and 185:
166
Page 186 and 187:
❘❙❚■ Chapter 17 | Types of
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
❘❙❚■ Chapter 18 | Significa
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
❘❙❚■ Chapter 19 | Compariso
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
216
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
234
Page 254 and 255:
❘❙❚■ Chapter 21 | Analysis
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
254
Page 274 and 275:
❘❙❚■ Chapter 22 | Intention
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
264
Page 284 and 285:
❘❙❚■ Chapter 23 | Subgroup
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
272
Page 292 and 293:
❘❙❚■ Chapter 24 | Regressio
Page 294 and 295:
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
286
Page 306 and 307:
❘❙❚■ Chapter 25 | Adjustmen
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
❘❙❚■ Chapter 26 | Confoundi
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
❘❙❚■ Chapter 27 | Interacti
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
❘❙❚■ Chapter 28 | Repeated
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
❘❙❚■ Chapter 29 | Multiplic
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
❘❙❚■ Chapter 30 | Missing D
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
352
Page 372 and 373:
❘❙❚■ Chapter 31 | Interim M
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
364
Page 384 and 385:
❘❙❚■ Chapter 32 | Overview
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
376
Page 396 and 397:
❘❙❚■ Chapter 33 | Trial Pro
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
❘❙❚■ Chapter 34 | Presentin
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
❘❙❚■ Chapter 35 | Use of Ta
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
406
Page 426 and 427:
❘❙❚■ Chapter 36 | Use of Fi
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
426
Page 446 and 447:
❘❙❚■ Chapter 37 | Critical
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
438
Page 458 and 459:
❘❙❚■ Chapter 38 | Meta-Anal
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
452
Page 472 and 473:
❘❙❚■ GlossaryANOVA (analysi
Page 474 and 475:
❘❙❚■ GlossaryHazard ratioIn
Page 476 and 477:
❘❙❚■ GlossaryPer-protocol a
Page 478 and 479:
460
Page 480 and 481:
❘❙❚■ Abbreviations3TCACEALL
Page 482 and 483:
❘❙❚■ AbbreviationsMDCMERIT-
Page 484 and 485:
466
Page 486 and 487:
❘❙❚■ IndexNote: Page number
Page 488 and 489:
❘❙❚■ Indexstratified random
Page 490 and 491:
❘❙❚■ IndexHhazard function,
Page 492 and 493:
❘❙❚■ Indexsignificance effe
Page 494 and 495:
❘❙❚■ IndexQqualitative inte
Page 496 and 497:
❘❙❚■ Indexpopulation, 186,
Page 498:
❘❙❚■ Indexwithin-subject va
show all

Clinical Trials

Create successful ePaper yourself

Delete template?

Save as template?